Diagnosis of Fibromyalgia Syndrome: Potential Biomarkers and Proteomic Approach

Ciregia, Federica; Giacomelli, Camillo; Giusti, Laura; Lucacchini, Antonio; Bazzichi, Laura

doi:10.5772/26979

Cited by 1 publication

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, FM comorbidity was assessed in patients with Hashimoto’s thyroiditis (HT) with or without subclinical hypothyroidism (SCH) and in patients with SCH alone [ 270 ]. Other authors who studied the role of the thyroperoxidase antibody (TPO Ab) have also reported results that implicate the thyroid in the etiopathogenesis of FM [ 271 ]. A high prevalence of thyroid autoantibodies in FM patients has been shown in repeated studies, but the role of TPO Ab in FM remains unclear [ 271 ].…”

Section: Serological Markersmentioning

confidence: 99%

“…Other authors who studied the role of the thyroperoxidase antibody (TPO Ab) have also reported results that implicate the thyroid in the etiopathogenesis of FM [ 271 ]. A high prevalence of thyroid autoantibodies in FM patients has been shown in repeated studies, but the role of TPO Ab in FM remains unclear [ 271 ]. Therefore, the proposed antibodies have not yet been validated as potent, useful diagnostic biomarkers for fibromyalgia, and further studies are required.…”

Section: Serological Markersmentioning

confidence: 99%

“…Given that IL-8 promotes sympathetic pain, it may play an important role in the frequency of pain in fibromyalgia. The IL-8 expression pattern could aid in the diagnosis of fibromyalgia and in effective treatment strategies if confirmed in further studies [ 271 ].…”

Section: Serological Markersmentioning

confidence: 99%

See 2 more Smart Citations

Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update

Siracusa

Paola

Cuzzocrea

et al. 2021

IJMS

280

223

View full text Add to dashboard Cite

: Fibromyalgia is a syndrome characterized by chronic and widespread musculoskeletal pain, often accompanied by other symptoms, such as fatigue, intestinal disorders and alterations in sleep and mood. It is estimated that two to eight percent of the world population is affected by fibromyalgia. From a medical point of view, this pathology still presents inexplicable aspects. It is known that fibromyalgia is caused by a central sensitization phenomenon characterized by the dysfunction of neuro-circuits, which involves the perception, transmission and processing of afferent nociceptive stimuli, with the prevalent manifestation of pain at the level of the locomotor system. In recent years, the pathogenesis of fibromyalgia has also been linked to other factors, such as inflammatory, immune, endocrine, genetic and psychosocial factors. A rheumatologist typically makes a diagnosis of fibromyalgia when the patient describes a history of pain spreading in all quadrants of the body for at least three months and when pain is caused by digital pressure in at least 11 out of 18 allogenic points, called tender points. Fibromyalgia does not involve organic damage, and several diagnostic approaches have been developed in recent years, including the analysis of genetic, epigenetic and serological biomarkers. Symptoms often begin after physical or emotional trauma, but in many cases, there appears to be no obvious trigger. Women are more prone to developing the disease than men. Unfortunately, the conventional medical therapies that target this pathology produce limited benefits. They remain largely pharmacological in nature and tend to treat the symptomatic aspects of various disorders reported by the patient. The statistics, however, highlight the fact that 90% of people with fibromyalgia also turn to complementary medicine to manage their symptoms.

show abstract

Section: Serological Markersmentioning

confidence: 99%

Section: Serological Markersmentioning

confidence: 99%